← All trials
NCT01835912
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 30, 2012
- Primary completion
- Mar 31, 2013
- Completion date
- Apr 30, 2013
- First posted
- Apr 19, 2013
- Last posted
- Jul 24, 2014
- Enrollment
- 10
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Brock UniversityLead sponsor
- Brock UniversityReponsible party - principal investigator
- Brock UniversityStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.